Neurturin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurturin is a secreted growth factor belonging to the GDNF family. The protein structure is characteristic of the TGF-β superfamily:
Neurturin is a potent neurotrophic factor that supports neuronal survival through specific receptor interactions:
| Approach | Status | Description |
|---|---|---|
| AAV2-NRTN (CERE-120) | Clinical trials | Gene therapy for PD |
| Recombinant protein | Preclinical | Protein delivery |
| Small molecule GFRα2 agonists | Research | Oral compounds |
| Cell therapy | Research | NRTN-expressing cells |
[1] Kordower, J.H. et al. (2000). Neurturin: Neurotrophic effects in a primate model of Parkinson's disease. Science 290, 767-773.
[2] Gasmi, M.J. et al. (2019). AAV2-Neurturin for Parkinson's disease. Mov Disord 34, 1243-1253.
[3] Li, W. et al. (2018). Neurturin and dopaminergic neuron survival. Mol Neurobiol 55, 7233-7242.
[4] Bohn, M.C. (2017). GDNF family ligand biology. Neurobiol Dis 100, 1-8.
The study of Neurturin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Neurturin (NRTN) is a member of the glial cell line-derived neurotrophic factor (GDNF) family, which includes GDNF, neurturin, artemin, and persephin. These proteins share a common structural fold and signal through the same receptor complex consisting of GFRalpha1-4 (or GDNFRalpha1-4) co-receptors and Ret receptor tyrosine kinase.
Neurturin binds primarily to GFRalpha2 (also known as GDNFRalpha2 or RETL1), which then recruits and activates Ret. This activation triggers downstream signaling through the PI3K/Akt, MAPK/ERK, and PLCgamma pathways, promoting neuronal survival, differentiation, and function.
Parkinson's Disease: Neurturin has been extensively studied as a potential neuroprotective therapy for PD. Clinical trials have investigated neurturin delivered via gene therapy (CERE-120) to the striatum. While initial trials showed some promise, later phases did not meet primary endpoints. Research continues on optimizing delivery and dosing.
Alzheimer's Disease: Neurturin may have protective effects on cholinergic neurons, potentially benefiting AD patients. Preclinical studies show neurturin can protect basal forebrain cholinergic neurons from amyloid-beta toxicity.
Huntington's Disease: Neurturin has shown neuroprotective effects in HD models, protecting striatal medium spiny neurons from mutant huntingtin toxicity.
Gene therapy approaches using AAV vectors to deliver the NRTN gene are being developed. Recent advances in vector design and delivery methods may improve therapeutic efficacy. Small molecule mimics of neurturin are also being explored.
Current research focuses on: (1) improving gene therapy delivery to target brain regions, (2) developing blood-brain barrier penetrating neurturin analogs, (3) understanding the specific neuronal populations responsive to neurturin, and (4) combination therapies with other neurotrophic factors.